Table 1.

Baseline characteristics of patients undergoing vedolizumab dose intensification

Characteristics	n=36
Gender, male:female (%)	26:10 (72:28)
IBD phenotype
Ulcerative colitis/IBD-U	18 (50%)
Left-sided	11
Extensive	7
Crohn’s disease	18 (50%)
Ileal	6
Colonic	4
Ileocolonic	8
Median age, years (range)	44 (17–70)
Concomitant immunomodulator use at baseline	18 (50%)
Thiopurine	17
Methotrexate	1
Prior anti-TNF exposure
Naïve	5 (14%)
Exposed	31 (86%)
Corticosteroid use at baseline	6 (16%)
Median duration of vedolizumab treatment before dose intensification, months (range)	7 (3–21)
Median duration of vedolizumab treatment after dose intensification, months (range)	7 (2–25)

IBD, inflammatory bowel disease; IBD-U, IBD-unclassified; TNF, tumour necrosis factor.